Imagine surviving a stroke, only to face a daunting choice: take one medication or two to prevent another life-threatening event. This is the reality for many stroke survivors, especially those with conditions like atrial fibrillation and atherosclerosis. For years, doctors have grappled with this decision, weighing the benefits of dual therapy against the risks. But here's where it gets controversial: a groundbreaking Japanese study published in JAMA Neurology (https://pubmed.ncbi.nlm.nih.gov/41051787/) suggests that less might actually be more.
The debate centers on antithrombotic agents—medications that prevent blood clots. For stroke survivors with nonvalvular atrial fibrillation (an irregular heartbeat) and atherosclerosis (hardening of the arteries), the question is whether combining an anticoagulant (like warfarin or a direct oral anticoagulant) with an antiplatelet drug (such as aspirin) offers better protection than using an anticoagulant alone. While dual therapy seems logical—after all, two drugs should work better than one, right?—it also doubles the risk of serious bleeding, a potentially life-threatening side effect.
To settle this, researchers conducted a large-scale trial across 41 medical centers in Japan, enrolling 316 patients who had recently experienced an ischemic stroke or transient ischemic attack (TIA). These patients were at high risk due to their atrial fibrillation and signs of atherosclerosis, such as narrowed arteries in the brain or legs. Half received an anticoagulant alone (monotherapy), while the other half received both an anticoagulant and an antiplatelet drug (combination therapy).
And this is the part most people miss: After up to two years of monitoring, the results were striking. While both groups had similar rates of new strokes or heart attacks (around 18-20%), the combination therapy group saw nearly double the rate of serious bleeding—almost one in five patients, compared to fewer than one in ten on monotherapy. The study was halted early because the minimal added benefit of dual therapy didn’t justify the significant bleeding risk.
This raises a thought-provoking question: Are we overcomplicating treatment for stroke survivors? For most patients with atrial fibrillation and atherosclerosis, a single anticoagulant appears to be the safer and smarter choice. However, there are exceptions—for instance, patients with heart stents may still need combination therapy. But for the majority, monotherapy could be the best path forward.
What do you think? Is less truly more when it comes to stroke prevention? Or do the potential benefits of dual therapy outweigh the risks in certain cases? Share your thoughts in the comments below!
References
Okazaki S, et al. JAMA Neurol. 2025:e253662. doi:10.1001/jamaneurol.2025.3662 (https://pubmed.ncbi.nlm.nih.gov/41051787/)
